Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced it will release its third quarter 2026 financial results on November 4, 2026. The company will host a conference call and webcast at 8:00 AM ET to discuss recent business progress and financial outcomes. Nuvectis focuses on innovative therapies for complement-related conditions and oncology, with key drug candidates including ciprocopan (NXP100) and oncology treatments NXP200 and NXP900. Investors can access the live webcast via the company's website, with a replay available for 30 days.
Nuvectis Pharma's upcoming Q3 2026 financial results provide context for health sector activity on Pluang. As of November 3, 2026 04:11 WIB, 48 of 150 priced health-sector US stocks rose while 100 fell. Notable movers include HIMS at USD 25.22 with a -8.89% change and 100% buy order activity, TVTX at USD 46.00 down -8.71%, and NTRA at USD 379.01 down -8.49%.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
Amazon.com is reinforcing its market position with AWS backlog surging to $580 billion and aiming for a $1 trillion revenue run rate. Despite concerns over aggressive AI-related capital expenditures and delayed free cash flow recovery, management jus...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
